A monoclonal antibody drug conjugate that specifically targets advancing bladder cancer cells.
Bladder cancer is a common form of cancer, which progresses by spreading into surrounding muscle. This advanced stage, called muscleinvasive bladder cancer (MIBC), is associated with poor prognosis due to a lack of effective treatment options.
Currently, treatment is restricted to the surgical removal of cancerous tissue combined with radiotherapy and/or chemotherapy, which are both associated with severe side-effects as they affect both cancerous and noncancerous cells. In addition, determining the appropriate therapeutic regime for bladder cancers is hampered by a lack of accurate imaging technology.
Antibody-drug conjugates (ADCs) use the specificity of antibodies to target only cancerous cells with a therapeutic agent. We are therefore developing a targeted ADC for MIBC.
The interleukin-5 receptor (IL5-Rα) has been validated as a biomarker of advancing bladder cancer. Therefore, cells expressing IL5-Rα can be targeted by ADCs for imaging and treatment respectively.
We have developed a monoclonal antibody (mAb), which can be conjugated with either a chemotherapeutic agent or a radioligand. In addition these mAb-conjugates have been packaged with additional structural technology for enhanced cellular accumulation in IL5-Rα (CD125)-positive MIBC cells.
We have validated the target for expression and internalisation and shown that the ADC is efficacious in human cancer cells. A radiolabelled Immunoconjugate (RIC) has also been generated that could be used for diagnostic purposes to accurately determine the extent of the cancer prior to undertaking a treatment plan.
The technology has use in the cancer therapeutic and diagnostic fields.
The technology is protected by PCT application CA 2018/050303
UniSA Ventures is seeking partners for licensing and co-development opportunities.
Some of these cookies are essential for the website to function correctly, while others may collect your personal information. In some cases, the personal information collected by our cookies may be shared with third party service providers.
For details about the categories of cookies that we use, and to set your cookie preferences, please select ‘More information’ before you continue. For an overview see our Privacy Statement, or review our Privacy Policy in full.